|Bid||92.15 x 900|
|Ask||92.65 x 1200|
|Day's range||89.60 - 92.89|
|52-week range||62.55 - 97.86|
|Beta (5Y monthly)||0.78|
|PE ratio (TTM)||16.40|
|Earnings date||24 Jul 2020 - 28 Jul 2020|
|Forward dividend & yield||4.72 (5.24%)|
|Ex-dividend date||14 Apr 2020|
|1y target est||93.69|
Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
There are plenty of reasons for investors to like big pharma stocks. They're usually resilient during economic downturns. Many of them have solid growth prospects. And nearly all of them pay dividends.
Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple
Top Ranked Income Stocks to Buy for May 22nd
AbbVie (ABBV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
With an economic revival in motion despite the unfavorable circumstances so far, value stocks offer the much-needed stability to one's portfolio.
AbbVie (ABBV) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The compounding effects of reinvesting dividends over the long-term can be spectacular - but finding stocks to help you do it is a challenge... The present eco...
Shares in Abbvie Inc (NYQ:ABBV) are currently trading at 91.47 but a key question for investors is how the economic uncertainty caused by Coronavirus will affe...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: JPMorgan Chase, AbbVie, Royal Dutch Shell, Gilead Sciences and Anthem
FDA approves Lilly's (LLY) selpercatinib for RET-altered lung and thyroid cancers and AstraZeneca (AZN)/Merck's (MRK) Lynparza for new ovarian cancer use.